Clinical trials - Press Releases

Date	Title	Company
11-Jul-2023	Phastar's B Corp™ certification affirms its status as a 'force for good' organization	Phastar
07-Jul-2023	Numaferm and Zoetis Sign License Agreement to Collaborate on Developing and Producing Proteins and Peptides	Numaferm
07-Jul-2023	AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients	AiCuris
07-Jul-2023	PSYCH Symposium 2023	PSYCH CAPITAL PLC
06-Jul-2023	ACTIPHAGE TB ENTERS THIRD CLINICAL TRIAL AIMED AT VALIDATING ITS UTILITY AS A TUBERCULOSIS DIAGNOSTIC	PBD Biotech
06-Jul-2023	TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing	TolerogenixX
04-Jul-2023	Psychedelics clinical trial start-up Clerkenwell Health to sponsor PSYCH Symposium London 2023	Clerkenwell Health
04-Jul-2023	Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia	Sosei Heptares
04-Jul-2023	Creative Diagnostics Introduces qPCR Assay for Rapid Virus Detection and Quantification	Creative Diagnostics
30-Jun-2023	Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer	Enterome
30-Jun-2023	DelSiTech announces positive topline clinical data from phase 1 trial with its sustained release eye drop platform	DelSiTech
30-Jun-2023	Teva’s 3rd interim analysis of PEARL real-world study on AJOVY® (fremanezumab) reveals sustained long-term effectiveness in reducing frequency, duration and severity of attacks in patients with chronic and episodic migraine	teva
29-Jun-2023	IgniteData and Leading New York City Cancer Center Collaborate to Solve the Clinical Trial Data Transfer Challenge	IgniteData
28-Jun-2023	Sotyktu™▼ (deucravacitinib) recommended for use on the NHS in England as a first-in-class treatment option for moderate to severe plaque psoriasis in adults	Bristol Myers Squibb (BMS)
28-Jun-2023	Dopavision Provides Clinical Trial Update and Announces All MyopiaX-1 Trial Sites Are Active	DopaVision
27-Jun-2023	Cyntegrity’s MyRBQM Portal, an AI-Supported Clinical Trial Risk Management Solution, is Now Available in the Microsoft Azure Marketplace	Cyntegrity
27-Jun-2023	GPCR passes Technology Evaluation process for listing on KOSDAQ	GPCR Therapeutics
27-Jun-2023	Sobi completes acquisition of CTI BioPharma Corp.	CTI BioPharma Corp.
27-Jun-2023	Commercial trial to treat major depressive disorder with psychedelic drugs given green light by MHRA	Clerkenwell Health
27-Jun-2023	DIPHARMA AND LOGIXX PHARMA ANNOUNCE GRANTING OF MARKETING AUTHORISATION APPROVAL FOR GENERIC SAPROPTERIN IN UNITED KINGDOM	Dipharma SA (“Dipharma”) and LogixX Pharma (“LogixX”)